Table 1 Details of each enrolled study
Author (Year) | Setting | Clinical trials register No. | Pre-protocol participants (I/C) | Participants completed study (I/C) | Intervention drug | Single dose | Frequency | Total dose | Routine | Control | Study duration | Outcomesa |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daley 2015 [11] | India | NCT00366470 | 247(121/126) | 211(101/110) | Vitamin D3 | 2·5 mg | Biweekly*4 doses | 10 mg | Oral | Placebo | 6 weeks | ①②③④⑤⑥⑮⑯ |
Ganmaa 2016 [12] | Mongolia | NCT01657656 | 390(190/200) | 352(174/178) | Vitamin D3 | 3.5 mg | Biweekly*4 doses | 13.5 mg | Oral | Placebo | 8 weeks | ①②③④⑤⑥⑧⑨⑩ ⑪ ⑫ ⑬ ⑭ ⑮ ⑯ |
Martineau 2011 [13] | UK | NCT00419068 | 146(73/73) | 126(62/64) | Vitamin D3 | 2·5 mg | Biweekly*4 doses | 10 mg | Oral | Placebo | 8 weeks | ①②③④⑤⑥⑧⑨⑩⑪⑫⑬⑭⑮⑯ |
Mily 2015 [14] | Bangladesh | NCT01580007 | 144(72/72) | 128(63/65) | Vitamin D3 | 0.875 mg | Weekly*8 doses | 7 mg | Oral | Placebo | 8 weeks | ②③⑤⑥⑦⑩⑫⑬⑭⑮⑯ |
Nursyam 2006 [15] | Indonesia | NM | 67(34/33) | 67(34/33) | Vitamin D3 | 0.25 mg | Per day*42 doses | 10.5 mg | Oral | Placebo | 6 weeks | ①⑨⑩ |
Salahuddin 2013 [16] | Pakistan | NCT01130311 | 259(132/127) | 238(119/119) | Vitamin D3 | 15 mg | Per month*2 doses | 30 mg | Intramuscular | Placebo | 8 weeks | ①⑤⑦⑧⑨⑩⑪⑯ |
Tukvadze 2015 [17] | Georgia | NCT00918086 | 199(100/99) | 192(97/95) | Vitamin D3 | 1.25 mg | Triweekly*3 doses and weekly*3 doses | 7.5 mg | Oral | Placebo | 16 weeks | ②④⑤⑥①⑤⑦⑧⑨⑩⑪⑯ |
Wejse 2009 [18] | Guinea | ISRCTN35212132 | 355(187/178) | 281(136/145) | Cholecalciferol | 2.5 mg | Four-monthly*3 doses | 7.5 mg | Oral | Placebo | 8 months | ①⑦⑩⑮⑯ |